Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLG | P00747 | 1/20 | 0.34 |
| ▸ | PLAT | P00750 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | THRA | P10827 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3425740 | 1.00 | PLG (0.34) | PLGPLATLMNATHRATHRB | |
| SCHEMBL929414 | 0.80 | PLG (0.56) | PLGPLATLMNA | |
| SCHEMBL3424858 | 0.80 | PLG (0.56) | PLGPLATLMNA | |
| Acetic Acid SCHEMBL3477522 | 0.79 | PLG (0.32) | PLGPLATLMNA | |
| Acetic Acid SCHEMBL3477520 | 0.79 | PLG (0.32) | PLGPLATLMNA | |
| SCHEMBL402037 | 0.78 | — | — | |
| SCHEMBL3425669 | 0.78 | TP53 (0.41) | — | |
| SCHEMBL243310 | 0.78 | TP53 (0.41) | — | |
| SCHEMBL3427797 | 0.76 | LMNA (0.36) | LMNA | |
| SCHEMBL928953 | 0.76 | LMNA (0.36) | LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1778712-B1 | 2-PROPYNYL ADENOSINE ANALOGS WITH MODIFIED 5'-RIBOSE GROUPS HAVING A2A AGONIST ACTIVITY | Univ Virginia Patent Found (US) | 2013-01-30 | — | — | EP | disclosed |
| US-8158604-B2 | 2-propynyl adenosine analogs having A2A agonist activity and compositions thereof | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2012-04-17 | — | — | US | disclosed |
| US-7989431-B2 | 4-{3-[6-Amino-9-(5-cyclopropylcarbamoyl-3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-cyclohexanecarboxylic acid methyl ester; for inflammation, such as organ, tissue or cell transplantation, angioplasty (PCTA), inflammation following ischemia/reperfusion, or grafting | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2011-08-02 | — | — | US | disclosed |
| US-20110136755-A1 | 2-PROPYNYL ADENOSINE ANALOGS WITH MODIFIED 5'-RIBOSE GROUPS HAVING A2A AGONIST ACTIVITY | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2011-06-09 | — | — | US | disclosed |
| US-7875595-B2 | 5-[6-Amino-2-(2-hydroxy-adamantan-2-ylethynyl)-purin-9-yl]-3,4-dihydroxy-tetrahydro-furan-2-carboxylic acid cyclopropylamide for the treatment of inflammatory activity in mammalian tissue; A2A adenosine receptor agonist; autoimmune stimulation, allergic diseases, skin diseases, infectious diseases | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2011-01-25 | — | — | US | disclosed |
| EP-2266994-A1 | 2-propynyl adenosine analgos with modified 5'-ribose groups having A2A agonist activity | University Of Virginia Patent Foundation (US) | 2010-12-29 | — | — | EP | disclosed |
| US-20100152127-A1 | 2-PROPYNYL ADENOSINE ANALOGS HAVING A2A AGONIST ACTIVITY AND COMPOSITIONS THEREOF | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2010-06-17 | — | — | US | disclosed |
| US-7737127-B2 | 2-propynyl adenosine analogs having A2A agonist activity and compositions thereof | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2010-06-15 | — | — | US | disclosed |
| US-20090298788-A1 | 2-POLYCYCLIC PROPYNYL ADENOSINE ANALOGS HAVING A2A AGONIST ACTIVITY | UNIVERSITY OF VIRGINIA PATENT FOUNDATION AND ADENOSINE THERAPEUTICS, L.L.C. | 2009-12-03 | — | — | US | disclosed |
| US-7605143-B2 | 2-propynyl adenosine analogs with modified 5′-ribose groups having A2A agonist activity | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2009-10-20 | — | — | US | disclosed |
| WO-2006015357-A9 | 2-PROPYNYL ADENOSINE ANALOGS WITH MODIFIED 5'-RIBOSE GROUPS HAVING A2A AGONIST ACTIVITY | UNIV VIRGINIA (US) | 2006-04-20 | — | — | WO | disclosed |
| WO-2006028618-A1 | 2-POLYCYCLIC PROPYNYL ADENOSINE ANALOGS WITH MODIFIED 5'-RIBOSE GROUPS HAVING A2A AGONIST ACTIVITY | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2006-03-16 | — | — | WO | disclosed |
| US-20060040888-A1 | 2-propynyl adenosine analogs with modifed 5'-ribose groups having A2A agonist activity | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2006-02-23 | — | — | US | disclosed |
| US-20060040889-A1 | 2-polycyclic propynyl adenosine analogs having A2A agonist activity | ADENOSINE THERAPEUTICS, L.L.C | 2006-02-23 | — | — | US | disclosed |
| WO-2006015357-A2 | 2-PROPYNYL ADENOSINE ANALOGS WITH MODIFIED 5'-RIBOSE GROUPS HAVING A2A AGONIST ACTIVITY | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2006-02-09 | — | — | WO | disclosed |
| EP-1496911-A1 | USE OF A2A ADENOSINE RECEPTOR AGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2005-01-19 | — | — | EP | disclosed |
| EP-1434782-A2 | 2-PROPYNYL ADENOSINE ANALOGS HAVING A2A AGONIST ACTIVITY AND COMPOSITIONS THEREOF | University of Virginia Patent Foundation (US) | 2004-07-07 | — | — | EP | disclosed |
| WO-2003086408-A1 | USE OF A2A ADENOSINE RECEPTOR AGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2003-10-23 | — | — | WO | disclosed |
| US-20030186926-A1 | 2-propynyl adenosine analogs having A2A agonist activity and compositions thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-10-02 | — | — | US | disclosed |
| WO-2003029264-A2 | 2-PROPYNYL ADENOSINE ANALOGS HAVING A2A AGONIST ACTIVITY AND COMPOSITIONS THEREOF | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2003-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298788-A1 | 2-POLYCYCLIC PROPYNYL ADENOSINE ANALOGS HAVING A2A AGONIST ACTIVITY | ADORA2A, ADORA3, ADORA1 | PLG 1962/4885PLAT 842/4885LMNA 1401/4885 |
| US-20060040889-A1 | 2-polycyclic propynyl adenosine analogs having A2A agonist activity | ADORA2A, ADORA3, ADORA1 | PLG 1962/4885PLAT 842/4885LMNA 1401/4885 |
| US-20110136755-A1 | 2-PROPYNYL ADENOSINE ANALOGS WITH MODIFIED 5'-RIBOSE GROUPS HAVING A2A AGONIST ACTIVITY | ADORA2A, ADORA3, ADORA1 | PLG 1714/4885PLAT 787/4885LMNA 902/4885 |
| US-20100152127-A1 | 2-PROPYNYL ADENOSINE ANALOGS HAVING A2A AGONIST ACTIVITY AND COMPOSITIONS THEREOF | ADORA2A, ADORA3, ADORA1 | PLG 2027/4885PLAT 932/4885LMNA 1231/4885 |
| US-20030186926-A1 | 2-propynyl adenosine analogs having A2A agonist activity and compositions thereof | ADORA2A, ADORA1, ADORA3 | PLG 2085/4885PLAT 960/4885LMNA 1558/4885 |
| US-20060040888-A1 | 2-propynyl adenosine analogs with modifed 5'-ribose groups having A2A agonist activity | ADORA2A, ADORA3, ADORA1 | PLG 2240/4885PLAT 1792/4885LMNA 1458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.